KIRhub 2.0· v2

Abrocitinib

809c459d-165a-5b10-9570-938dce4d32ee · FDA Approved · targets JAK1

Abrocitinib

MeasuredReference

Abrocitinib targets JAK1, JAK2, TYK2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

Top hallmarks

tumor promoting inflammation2.6k
evading apoptosis1.6k
proliferation1.6k

Top pathways disrupted

pi3k akt mtor signaling3.7k
interferon gamma response3.4k
allograft rejection3.3k

Resistance landscape — Abrocitinib

MeasuredReference

4 known oncogenic variants exist on Abrocitinib's top targets — see detail for inhibition impact.

JAK2 1 known variant
- JAK2 (V617F)
LRRK2 3 known variants

Open in new tab